000			01342nam a2200277 4500
001			ESSALUD
005			20260821151611.0
007			ta
008			t pe ||||| |||| 00| 0 spa d
040			_aBMG
041			_aeng
100			_aSchett, Georg _eAutor _954286
245			_aPregnancies in patients with autoimmune disease receiving CAR T-cell therapy
300			_apáginas: 821-824
520			_aAutoimmune diseases preferentially affect women in their childbearing years, potentially interfering with reproduction. Pregnancies in patients with autoimmune diseases are associated with increased maternal and fetal risks. Treatment of autoimmune diseases with autologous CD19–chimeric antigen receptor (CAR) T cells has been shown to lead to sustained drug-free remission, which is expected to be associated with improved pregnancy outcomes.
650			_aENFERMEDAD AUTOINMUNE _953665
650			_aCOMPLICACIONES DEL EMBARAZO
650			_aENDOCRINOLOGÍA GENERAL _954270
650			_aCÉLULAS T _954097
700			_aWirsching, Andreas _954287
700			_aRothe, Tobias _954288
700			_aVisconti, Vanessa _954289
700			_aKramer, Neil _954290
773	0		_022717 _922650 _dMassachusetts NEJM Group _oNEJM12 _tThe New England Journal of Medicine _wESSALUD _x0028-4793
942			_cARTICULOS _e2026-08-21 _zsqb
999			_c22860 _d22860